Table 2 Clinicopathologic characteristics of 120 septic patients with genetic variants in the prolyl-hydroxlase 2 gene (SNP rs516651)

Patients characteristics

 Gender (women/men; %)

38/58 (39.6/60.4)

5/16 (23.8/76.2)

1/2 (33.3/66.7)

0.094**

 age (years; median; Q1; Q3)^b

55 (44–68)

58 (53–65)

71 (50–71)

0.201*

 height (cm; median; Q1; Q3)^b

172 (165–180)

179 (170–184)

185 (156–185)

0.342*

 body weight (kg; median; Q1; Q3)^b

80 (65–90)

90 (77–110)

78 (75–78)

0.205*

 BMI (kg/m²; median; Q1; Q3)^b

26.2 (22.8–30.8)

28.1 (25.3–34)

26.3 (22.8–26.3)

0.434*

 Heart rate (min⁻¹; median, Q1; Q3)^b

100 (90–121)

113 (94–156)

90 (70–90)

0.063*

 Mean arterial blood pressure (mmHg; median; Q1; Q3)^b

75 (63–87)

73 (61–87)

76 (63–76)

0.850*

 creatinin serum concentration (mg dl⁻¹; (median; Q1;Q3)^b

1.66 (0.97–2.85)

1.73 (0.96–2.08)

1.16 (1.15–1.16)

0.874*

 Dialysis (yes/no; %)

62/34 (64.6/35.4)

14/6 (70/30)

3 (100)

0.619**

Primary diagnoses %

 Cardiovascular disease

5 (6.2)

2 (11.1)

1 (33.3)

^c

 Hematooncological disease

3 (3.7)

2 (11.1)

 Gastrointestinal disease

33 (40.7)

4 (22.2)

 Lung disease

19 (23.5)

5 (27.8)

1 (33.3)

 Urogenital cancer

6 (7.4)

1 (5.6)

 Intraabdominal pathology, other Cancer, other

15 (18.4)

4 (22.2)

1 (33.3)

Infectious variables

 White blood cell count (10⁹ l⁻¹; median; Q1; Q3)^b

13.8 (9.3–20.6)

15.5 (8.9–19.1)

15.6 (12.2–15.6)

0.961*

 Procalcitonin concentration (μg l⁻¹; median; Q1; Q3)^b

3.97 (1.2–15.7)

3.46 (0.31–9.93)

0.5 (0.23–0.5)

0.699*

 C-reactive protein concentration (g l⁻¹; median; Q1; Q3)^b

17.7 (9.1–27.3)

15 (8–21.5)

18.4 (0.5–18.4)

0.603*

Disease severity

 SAPS II^d (mean ± SD)^a

35 (27–44)

38 (30–50)

48 (41–48)

0.107*

 Hospital stay (d; mean ± SD)^a

23 (12–35)

29 (11–56)

21 (9–21)

0.071*

 30-day mortality (%)

33 (34.4)

8 (38.1)

2 (66.7)

0.103**